Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences - United States
doi 10.1007/s10620-018-4952-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Persistence and Failure Rates of Adalimumab Monotherapy in Biologic-Naïve Patients With Psoriasis: A Retrospective Study

Journal of the American Academy of Dermatology
Dermatology
2016English

Safety Profile of Biologic Therapy in Polish Paediatric Patients With Crohn’s Disease

Przeglad Gastroenterologiczny
Gastroenterology
2015English

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

Journal of Comparative Effectiveness Research
Health Policy
2019English

Exclusive Enteral Nutrition Versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease

Gastroenterology Research and Practice
HepatologyGastroenterology
2017English

Clinical Experience With Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta

Canadian Journal of Gastroenterology
2002English

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy